TY - JOUR
T1 - N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells
AU - Dagvadorj, Ayush
AU - Tan, Shyh Han
AU - Liao, Zhiyong
AU - Xie, Jianwu
AU - Nurmi, Martti
AU - Alanen, Kalle
AU - Rui, Hallgeir
AU - Mirtti, Tuomas
AU - Nevalainen, Marja T.
N1 - Funding Information:
Shared Resources of KCC are partially supported by NIH Grant CA56036-08 (Cancer Center Support Grant, to KCC). This work was supported by ACS ( RSG-04-196-01-MGO ), DOD ( W81XWH-05-01-0062 and W81XWH-07-1-0411 ) and NIH NCI ( 1RO1CA113580-01A1 ) grants.
PY - 2010/12
Y1 - 2010/12
N2 - Transcription factor Stat5a/b is critical for prostate cancer cell survival and for prostate xenograft tumor growth. In addition, the Stat5a/b signaling pathway may contribute to progression of organ-confined prostate cancer to castration-resistant and/or metastatic disease. Expression of nuclear Stat5a/b is clustered to high grade human prostate cancers, and nuclear Stat5a/b in primary prostate cancer predicts early disease recurrence after initial treatment. Here, we show by Western blotting and electromobility shift assay that Stat5a/b protein in human prostate cancer is N-terminally truncated. This short form of Stat5a/b is generated post-translationally in vivo in prostate cancer cells and is the predominant form of Stat5a/b that binds to DNA. We further demonstrate by mutagenesis and co-immunoprecipitations that the N-domain of Stat5a/b is required for binding to PIAS3, and that PIAS3 inhibits transcriptional activity of Stat5a/b in breast cancer cells but not in prostate cancer cells. Thus, the proteolytic cleavage of the N-terminus of Stat5a/b may be a mechanism by which Stat5 evades the transcriptional repression by PIAS3 in prostate cancer cells, and results in increased Stat5-driven gene expression and prostate cancer progression.
AB - Transcription factor Stat5a/b is critical for prostate cancer cell survival and for prostate xenograft tumor growth. In addition, the Stat5a/b signaling pathway may contribute to progression of organ-confined prostate cancer to castration-resistant and/or metastatic disease. Expression of nuclear Stat5a/b is clustered to high grade human prostate cancers, and nuclear Stat5a/b in primary prostate cancer predicts early disease recurrence after initial treatment. Here, we show by Western blotting and electromobility shift assay that Stat5a/b protein in human prostate cancer is N-terminally truncated. This short form of Stat5a/b is generated post-translationally in vivo in prostate cancer cells and is the predominant form of Stat5a/b that binds to DNA. We further demonstrate by mutagenesis and co-immunoprecipitations that the N-domain of Stat5a/b is required for binding to PIAS3, and that PIAS3 inhibits transcriptional activity of Stat5a/b in breast cancer cells but not in prostate cancer cells. Thus, the proteolytic cleavage of the N-terminus of Stat5a/b may be a mechanism by which Stat5 evades the transcriptional repression by PIAS3 in prostate cancer cells, and results in increased Stat5-driven gene expression and prostate cancer progression.
KW - N-terminal truncation
KW - PIAS3
KW - Prostate cancer
KW - Stat5a/b
UR - http://www.scopus.com/inward/record.url?scp=78149283094&partnerID=8YFLogxK
U2 - 10.1016/j.biocel.2010.09.008
DO - 10.1016/j.biocel.2010.09.008
M3 - Article
C2 - 20854925
AN - SCOPUS:78149283094
SN - 1357-2725
VL - 42
SP - 2037
EP - 2046
JO - International Journal of Biochemistry and Cell Biology
JF - International Journal of Biochemistry and Cell Biology
IS - 12
ER -